BioMoti

We are very pleased to announce our collaboration with a global #pharmaceutical company to develop our #BMT101 #ovariancancer #drug candidate to phase 2a #clinicaltrials and the appointment of Dr John Beadle as our new Chairman. #Oncojans #Cancer bit.ly/3wqYlKg

.@BioMoti announces collaboration with global #pharmaceutical company to develop #ovariancancer treatment, BMT101, to clinical phase 2a proof-of-concept and appoints Dr John Beadle as Chairman. sciadnewswire.com/news/724/biomo…

Read our new #InspiringWomen Profile of the amazing Professor Joanne Martin- Professor of Pathology at @QMUL and founder of @BioMoti, a company engineering cancer therapeutics to ensure effective treatment with fewer side effects 🔬⬇️👩‍🔬 bit.ly/InspiringWomen… #WomenInSTEM

Our final BioLaunchPad company showcase of the day is presented by @BioMoti #biotrinity #biotrinity2019 #lifesciences #investment #biopartnering #showcase

We have a packed schedule of BioLaunchPad presentations at #BioTrinity this year including @mycoBiologics @AVIPERO @oxfordni @Nosopharm @BioMoti @mip_dx @BRAINCURES @HUMABODY AND MANY MORE! #Innovation #Showcase #Networking #LifeSciences

"Avoid people who operate with the process-focused approach of a big #pharma or without the set of skills needed to operate in a dynamic #biotech startup" #startup #startuplife #biotech #Forbion #AurorA-TT @BioMoti @medicxi bit.ly/2DNldbT

Many congratulations to Medi-Immune on the win and thank you to all those who voted for @BioMoti. It was an honour to be shortlisted amongst such great news flow for the sector in 2017! twitter.com/onenucleus/sta…

Please vote for @QMUL to win @OneNucleus BioNewsRound Award 2017: bit.ly/2jqkfGX. We were shortlisted for our @innovateuk #BiomedicalCatalyst funding in collaboration with @BioMoti & @Pharmidex to work on the new #Oncojan technology for hard to treat cancers

ICYMI: Please vote here for us to win: bit.ly/2jqkfGX @OneNucleus BioNewsRound Award 2017 final. Our story exemplifies resilience as an early stage biotech & our collaborative approach to de-risk our early science to address unmet clinical needs. #Oncojans #ovariancancer

Please vote @BioMoti - shameless plug for our start up, working to bring our ovarian cancer drug delivery system into practice! From microscope observation into potential cancer therapy.... twitter.com/onenucleus/sta…

@BioMoti, @Pharmidex & @QMUL are proud our @innovateuk #BiomedicalCatalyst funding is a @OneNucleus BioNewsRound Award 2017 finalist. Our story exemplifies resilience & our collaborative approach to de-risk early science. Please vote here for us to win: bit.ly/2jqkfGX